CCBIO/CMYC Seminar October 29, 2026 – Anna Lübking
Welcome to the CCBIO seminar series in the fall term of 2026! Open to all in auditorium 4, BBB. No registration necessary. Speaker is Dr Anna Lübking, Skåne University Hospital, Lund, Sweden.
Speaker
Dr Anna Lübking, Skåne University Hospital, Lund, Sweden.
Title
Resistance or just slow? Management of treatment failure in CML
Chair
Bjørn Tore Gjertsen
Place
Auditorium 4, BB-building (external link)
When
October 29, 2026, at 14.30–15.30
No registration necessary. Note that if you are a UiB student and need the ECTS for participation, you need to have registered in Studentweb for this term.
Abstract
Tyrosine kinase inhibitors have brought survival in chronic phase CML close to that of the background population, but a substantial minority of patients fail to reach their treatment milestones, and here guidelines give limited direction. This session addresses the management of such patients.
Definitions of response will be discussed and illustrated by clinical cases, distinguishing true resistance from intolerance, and both from suboptimal molecular response that may not warrant a change of agent. We will then move on to selection of TKI in second and subsequent lines, and how mutation status, comorbidity, toxicity profile and especially the patient's individual treatment goal impact treatment choice.